Zealand Pharma A/S / Fundamentals
Income statement
- Net revenue
€1.22B - Cost of goods sold
-€722.64K - Gross profit
€1.22B - SG&A expenses
€38.33M - R&D expenses
€170.30M - EBITDA
€974.04M - D&A
€3.30M - EBIT
€961.74M - Interest expenses
€4.97M - EBT
€966.06M - Tax expenses
€71.50M - Net income
€894.56M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€119.29M - Changes in working capital
-€20.74M - Operating cash flow
€1.01B - Capex
€2.55M - Other investing cash flow
-€631.86K - Net investing cash flow
-€929.74M - Total cash dividends paid
€0.00 - Issuance of common stock
€4.80M - Debt repayment
€0.00 - Other financing cash flow
-€2.68M - Net financing cash flow
-€78.65M - Foreign exchange effects
-€22.58M - Net change in cash
-€21.02M - Cash at end of period
€969.96M - Free cash flow
€1.01B
Balance sheet
- Cash and cash equivalents
€969.96M - Cash and short-term investments
€2.22B - Total receivables
€24.43M - Inventory
€1.38M - Other current assets
€32.71M - Total current assets
€2.28B - Property, plant & equipment
€17.96M - Goodwill
€0.00 - Intangible assets
€1.82M - Long-term investments
€0.00 - Other non-current assets
€2.21M - Total non-current assets
€22.11M - Total assets
€2.30B - Accounts payable
€41.81M - Short-term debt
€4.69M - Other current liabilities
€32.70M - Total current liabilities
€150.96M - Long-term debt
€50.81M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€6.93M - Total non-current liabilities
€59.43M - Total liabilities
€210.39M - Common stock
€9.55M - Retained earnings
€107.55M - Other equity
€3.10M - Total equity
€2.09B - Total liabilities and shareholders' equity
€2.30B
Company information
- Market capitalization
€3.56B - Employees
385 - Enterprise Value
€33.40B
Company ratios
- Gross margin
-
100.1% Much better than peer group: 53.2% - EBITDA margin
-
79.9% Much better than peer group: 8.3% - EBIT margin
-
78.8% Much better than peer group: 3.3% - EBT margin
-
79.2% Much better than peer group: 2.6% - Net margin
-
73.3% Much better than peer group: -7.8% - ROE
-
42.8% Much better than peer group: 2.2% - ROA
-
38.9% Much better than peer group: 2.7% - Asset turnover
-
53.0% Worse than peer group: 60.1% - FCF margin
-
82.6% Much better than peer group: -8.7% - FCF yield
28.3% - Efficiency ratio
20.1% - Net sales per employee
-
€3.17M - Net income per employee
-
€2.32M